

Index

- acanthamebiasis
 testicular involvement, 36
- acantholytic dermatosis of the vulvocrual area, 337
- acromegaly, 16
- actinomycosis
 related to IUD, 13
- Addison disease, 21, 28
- adenocarcinoma
 seminal vesicle, 136–37
 urachus, 323–25
 urethra (female), 39–40
 urethra (male), 296–301
- adenofibroma
 uterus, 196–97
- adenomatous hyperplasia of the rete testis,
 39–40
- adenomyoma
 uterus, 194–95
- adenomyosis, 304
- adenosarcoma
 uterus, 197–98
- adipose tissue heterotopia, 29
- adnexal lesions
 penis, 377–79
 vulva, 377–79
- adrenal cortical ectopia
 testis, 28–29
- adrenogenital syndrome, 28–29
- aggressive angiomyxoma
 penis, 383
 vagina, 226–27
 vulva, 226–27, 383
- allergic eczema
 penis, 343
- 5- α reductase deficiency, 60
- alveolar soft part sarcoma
 uterus, 225
- amebiasis
 testicular involvement, 36
- anal folds, 5
- anal membrane, 5
- androgen insensitivity syndrome (AIS), 107
 complete AIS (CAIS), 26, 58–60
 minimal or slight AIS (MAIS), 58–60
 partial AIS (PAIS), 58–60
 testis, 26
- androgens, 5
- angiokeratoma
 penis, 344, 380
 vulva, 380
- angiomyofibroblastoma
 penis, 383–85
 vagina, 225–26
 vulva, 225–26, 383–85
- angiomyolipoma
 kidney, 203–8
- angiomyolipoma with epithelial cysts (AMLEC)
 kidney, 205–6
- angiosarcoma
 breast, 166
 uterus, 225
- anogenital mammary-like gland lesions
 penis, 377–79
 vulva, 377–79
- anorectal canal, 4
- antimüllerian hormone (AMH), 5
- antisperm-specific antibodies (ASA), 33
- aphthous ulcers
 vulva, 337
- Arias–Stella reaction
 endometrium, 186
- aspergillosis, 13
- Aspergillus fumigatus*, 36
- atopic dermatitis
 vulva, 333
- atresia, 8
- atypical polypoid adenomyoma (APAM)
 uterus, 195–96
- autoimmune disorders, 21
- autoimmune oophoritis, 21–22
- balanitis circinata, 340
- balanitis xerotica obliterans, 343
- Bartholin duct cysts
 vulva, 373
- Bartholin gland adenoma
 vulva, 377
- Bartholin gland carcinoma
 penis, 367–68
 vulva, 367–68
- Bartholin gland cysts, 133
 vulva, 376
- Bartholin gland hyperplasia
 vulva, 376–77
- Bartholin gland lesions
 vulva, 376–77
- basal cell carcinoma
 penis, 363–64
 vulva, 363–64
- Behçet disease, 32
 vulva, 337
- benign epithelial proliferations
 prostate and breast compared, 157
- benign prostatic hyperplasia (BPH), 130, 157
- biphasic tumors
 carcinosarcoma (prostate), 143
 definition, 140
 female genital tumors, 140
 male genital tumors, 140
 mixed epithelial and stromal tumors (seminal
 vesicles), 143–44
 prostate, 140–43
 sarcomatoid carcinoma (prostate), 143
 seminal vesicles, 143–44
 stromal sarcoma (prostate), 140–43
 STUMP (prostate), 140–43
- bladder
 classification and grading of surgical specimens,
 254
 condyloma acuminata, 277
 embryonic development, 4
 endometriosis, 304–6
 flat and papillary urothelial hyperplasia, 254–55
 flat neoplasms, 254–58
 grading heterogeneous papillary urothelial
 neoplasms, 261
 grading of urothelial carcinoma, 254
 infiltrating urothelial carcinomas, 262–69
 inverted (endophytic) neoplasms, 262
 inverted urothelial papilloma, 258–59
 keratinizing squamous cell metaplasia, 276
 low-grade papillary carcinoma, 260
 malignancy arising from endometriosis, 306
 micropapillary urothelial carcinoma, 278–80
 Müllerian lesions, 304–7
 neuroendocrine tumors, 233–35
 non-invasive urothelial lesions, 254–62
 papillary neoplasms, 258–61
 papillary urothelial neoplasm of low malignant
 potential (PUNLMP), 259–60
 paraganglioma, 233–34
 squamous cell carcinoma, 275–76
 squamous cell metaplasia, 276
 squamous cell papilloma, 277
 transitional cell tumors, 254–72
 urothelial carcinoma in situ (CIS), 255–58
 urothelial carcinoma variants, 262–69
 urothelial carcinoma with squamous
 differentiation, 275
 urothelial dysplasia, 255
 urothelial papilloma, 258–59
 urothelial proliferation of uncertain malignant
 potential (UPUMP), 254–55
 verrucous carcinoma, 276–77
- bladder cancer assessment and reporting
 adipose tissue, 271
 lamina propria, 269–70
 lymph nodes, 272
 lymphovascular invasion, 271–72
 muscularis propria, 270–71
 prostate involvement, 272
- bladder trigone
 embryonic development, 4
- blastomycosis, 13, 36
- Bowen disease
 penis, 354
 vulva, 348
- Bowman's capsule, 4
- breast
 adenosis, 157
 atypical ductal hyperplasia (ADH), 157
 benign epithelial proliferations, 157
 ductal carcinoma in situ (DCIS), 157
 histology compared to the prostate, 155–57

Index

- breast (cont.)
 intraepithelial proliferative lesions, 157
 microscopic anatomy compared to the prostate, 155
 similarities and differences to the prostate, 157
 specimen handling compared to prostate specimens, 167–68
 usual ductal hyperplasia (UDH), 157
- breast cancer
 angiosarcoma, 166
 genetic changes compared to prostate cancer, 166
 grading compared to prostate cancer, 161–63
 histologic variants compared to prostate cancer, 164
 intraductal carcinoma, 163–64
 mesenchymal tumors, 164–66
 metastatic tumors, 164–66
 pathologic features compared to prostate cancer, 158–61
 treatment compared to prostate cancer, 167
 use of frozen sections, 166–67
- Brenner tumors, 79
 ovary, 247–48
 ovary (borderline), 248–51
 ovary (malignant), 248–51
- brucellosis
 epididymis, 36
 testis, 36
- bulb-urethral gland
 embryonic development, 6
- bullous pemphigoid
 vulva, 336
- canal of Nuck cysts
 vulva, 374
- cancer genetic changes
 prostate cancer and breast cancer compared, 166
- cancer grading
 prostate cancer and breast cancer compared, 161–63
- cancer treatment
 prostate cancer and breast cancer compared, 167
- candidiasis, 36
 penis, 339
- carcinosarcoma
 ovary, 200–1
 prostate, 143
 uterus, 198–99
- Carney complex, 105
- caruncle
 urethra, 287
- cellular angiofibroma
 penis, 385
 vulva, 385
- ceroid granuloma of the testis and epididymis, 34
- cervix
 clear cell carcinoma, 184
 condyloma acuminata, 274
 lymphoma-like lesion, 225
 mesenchymal tumors, 225
 neuroendocrine tumors, 238–40
 postoperative spindle cell nodule, 225
 squamotransitional tumors, 274
 squamous papilloma, 274
 transitional cell metaplasia, 274
- chancroid
 penis, 339
- chemotherapy
 effects on the ovary, 22
- Chlamydia trachomatis*, 13, 32, 340
- cholesterol granulomas
 testis, 41
- choriocarcinoma
 ovary and testis, 95–98
- choristoma, 304
- chromophobe renal cell carcinoma with clear cell features, 174
- clear cell adenocarcinoma
 urethra (female), 291–94
 urethra (male), 301
- clear cell carcinoma
 ovary, 181–83, 184
- clear cell carcinoma (urinary tract and ovary compared), 310
 additional diagnostic considerations, 311–14
 clear cell carcinoma of the bladder mimicking nephrogenic adenoma, 313–14
 epidemiology and clinical characteristics, 310
 histogenesis of clear cell carcinoma in the urinary tract, 311
 histopathology, 310–11
 immunohistochemistry, 311
 true Müllerian clear cell carcinoma of the bladder associated with endometriosis, 313
 true Müllerian clear cell carcinoma of the bladder associated with Müllerian elements, 313
- clear cell renal cell carcinoma, 173
- clear cell tubulopapillary renal cell carcinoma (CCPRCC), 176–78
- clear cell tumors
 gynecologic tract, 179–86
 kidney, 173–79
 ovary, 181–84
- clitoris
 embryonic development, 8
- cloaca, 4
- cloacal folds, 5
- cloacal membrane, 5
- coccidioidomycosis, 13, 36
- collecting tubules
 embryonic development, 4
- combined sarcoma and epithelial tumor
 ovary, 202
- condyloma acuminata
 bladder, 277
 cervix, 274
 penis, 375–76
 vulva, 346–48, 375–76
- congenital adrenal hyperplasia, 16
- congenital lesions
 ovary, 22
- congenital testicular lymphangiectasis, 26–27
- contact dermatitis
 vulva, 333–34
- corpus luteum cyst
 ovary, 15
- Cowper gland cysts, 131
- Cowper glands-associated lesions, 289
- Crohn disease, 14
 vulva, 337
- cryptococcosis, 36
- cryptorchidism, 24, 25, 28
 seminiferous tubule ectopia, 27–28
- Cushing disease, 28
- Cushing syndrome, 21, 109
- cystadenocarcinoma
 prostate, 133–34
- cystadenoma
 seminal vesicles, 135–36
- cystic dysplasia of the epididymis, 25
- cystic dysplasia of the rete testis, 24–25
- cystic lesions
 analogy between prostate and gynecologic tract tumors, 137–36
 Bartholin gland cysts, 133
 Cowper gland cysts, 131
 features of female urogynecologic lesions, 128–29
- features of male prostatic and urologic cystic lesions, 128–29
- female homologs of the prostate and associated structures, 131–32
- female non-neoplastic cysts, 132–33
- female urogynecologic cysts, 131–33
- Gartner duct cysts, 132–33
- male neoplastic lesions, 133–37
- male non-neoplastic cysts, 129–31
- Müllerian cyst (female), 132
- penis, 373
- prostate cysts (neoplastic), 133–35
- prostate cysts (non-neoplastic), 129–30
- seminal vesicle cysts (neoplastic), 135–37
- seminal vesicle cysts (non-neoplastic), 130–31
- Skene duct cysts, 132
- syringocoele, 131
- vas deferens cysts, 131
- vulva, 373–74
- cystic nephroma, 189–90
- cystic transformation of the rete testis, 39
- cysts
 paratesticular cysts, 41–42
 solitary cysts of the ovary, 14–15
- cytomegalovirus oophoritis, 13
- Darier disease
 vulva, 336
- definitive urogenital sinus, 4
- Denys–Drash syndrome, 52
- dermatolipoma, 374
- dermatomyositis, 32
- diabetes, 374
- dihydrotestosterone (DHT), 5
- disorders of sexual development (DSD)
 46,XX pure gonadal dysgenesis, 51
 46,XY pure gonadal dysgenesis, 51–52
 absence of gonads (true agonadism), 50
 5- α reductase deficiency, 60
 androgen insensitivity syndrome (AIS), 58–60
 asymmetric gonadal differentiation, 53–54
 CAIS (complete androgen insensitivity syndrome), 58–60
 classification systems, 45–46
 defective androgen synthesis, 57–58
 defective Leydig cell function, 57–58
 defective peripheral action of androgens, 58–60
 definition, 45
 dysgenetic male pseudohermaphroditism, 54
 dysgenetic testis, 48–49
 gonadal dysgenesis, 50–55
 gonadal dysgenesis with classical streak gonads, 50–51
 gonadal dysgenesis with streak gonads with epithelial cords, 51–52
 hernia uteri inguinalis, 54–55
 histological classification, 45–46
 hypoplastic ovary, 47
 karyotype classification, 45
 Leydig cell hypoplasia, 58
 MAIS (minimal or slight androgen insensitivity syndrome), 58–60
 male with uterus, 54–55
 mixed gonadal dysgenesis, 53–54
 mosaicism, 45, 47
 normal male development, 45
 ovotestes, 49–50, 55–57
 PAIS (partial androgen insensitivity syndrome), 58–60
 persistent Müllerian duct syndrome, 54–55
 Sohval syndrome, 53–54
 streak gonad, 46–47
 streak gonad with epithelial cord-like structures, 47–48
 streak testis, 49
 structurally normal testis, 50

- structurally normal testis (male undervirilization), 57–60
 Swyer syndrome, 51–52
 testicular feminization, 58–60
 true hermaphroditism, 55–57
 Turner syndrome, 50–51
 types of gonads correlated with clinical syndromes, 46–50
 undifferentiated gonadal tissue (UGT), 46
 with dysgenetic testis and/or streak testis, 52–55
- distal convoluted tubule, 4
 ductus epididymidis ectopia, 29
 dysgerminoma
 ovary, 91–93, 184
- ectopias
 testis, 27–29
- ectopic decidua
 ovary, 20–21
- ectopic prostatic tissue
 in females, 145–48
 in males, 148
 normal-appearing tissue in ectopic sites, 145
 teratomas, 145
- eczematous dermatitis
 vulva, 333
- effluent tubules
 embryonic development, 4
- ejaculatory duct cysts, 129
 ejaculatory ducts, 126
 embryonic development, 4, 5
- embryonal carcinoma
 ovary and testis, 93
- embryonic development
 chronology of main stages, 8
 differentiation of the female gonad, 5
 differentiation of the indifferent gonad, 4–5
 differentiation of the male gonad, 5
 external genitalia, 5
 fate of indifferent drafts, 4–5
 female sexual differentiation, 6–8
 genital ridges, 4
 genital tract, 5
 indifferent stage, 4–5
 male sexual differentiation, 5–6
 pre-sex determination stage, 4–5
 primordial germ cells, 4
 urinary system, 3–4
- endocervicosis
 genitourinary tract, 306–7
 urinary tract, 304
- endometrial stromal and related tumors
 uterus, 217–20
- endometrial stromal nodule
 uterus, 217–18
- endometrioid carcinoma
 ovary, 184
- endometriosis
 bladder, 304–6
 epididymis, 41
 kidney, 306
 malignancy arising from, 306
 testis, 41
 ureter, 305–6
 urethra, 290, 306
 urinary tract, 304
 vulva, 380–81
- endometrium
 Arias–Stella reaction, 186
 neuroendocrine tumors, 240–41
- endosalpingiosis
 genitourinary tract, 306–7
 urinary tract, 304
- Enterobius vermicularis* infections, 14
- epidermal inclusion cysts
 vulva, 374
- epididymis
 acute orchio-epididymitis, 32–33
 brucellosis, 36
 ceroid granuloma of the testis and epididymis, 34
 cholesterol granulomas, 41
 chronic epididymitis, 33
 cystic dysplasia of the epididymis, 25
 embryonic development, 4, 5
 endometriosis, 41
 epididymitis nodosa, 41
 fibrous pseudotumor, 42
 fungal orchio-epididymitis, 36
 granulomatous orchio-epididymitis, 35–37
 inflammatory pathology, 32–37
 ischemic granulomatous epididymitis, 40–41
 malakoplakia, 34
 non-granulomatous orchio-epididymitis, 32–35
 sarcoidosis, 36
 sperm granuloma, 41
 tuberculosis, 35
 xanthogranulomatous orchio-epididymitis, 34–35
- epithelial lesions
 penis, 374–76
 vulva, 374–76
- epithelial tumors
 Brenner tumors of the ovary and testis, 79
 clear cell tumors of the ovary and testis, 77–78
 endometrioid tumors of the ovary and testis, 75–77
 features of ovarian tumors, 62
 mucinous tumors of the ovary and testis, 73–75
 origins of ovarian and testicular tumors, 62–64
 ovarian-type tumors of the testis, 62
 seromucinous tumors of the ovary and testis, 79–80
 serous tumors of the ovary and testis, 64–73
 undifferentiated carcinoma of the ovary, 80
- epithelioid angiomyolipoma
 kidney, 179, 206–8
- epoophoron, 150
- Erdheim–Chester disease
 testis, 34–35
- erythroplasia of Queyrat
 penis, 354
- Escherichia coli* infection, 32, 131
- estrogen, 8
- Exophiala jeanselmei*, 36
- external genitalia
 embryonic development, 5
- extramammary Paget disease
 penis, 356, 364–65
 vulva, 364–65
- female adnexal tumor of probable Wolffian origin (FATWO), 137
- female sexual differentiation, 6–8
 chronology of main stages of development, 8
 development of female external genitalia, 8
 development of the female genital tract, 8
 development of the ovary, 6–8
 fate of indifferent drafts, 8
- fetal gonadoblastoid testicular dysplasia (FGTD), 25
- FGF9* gene, 5
- fibroblastic lesions
 penis, 383–85
 vulva, 383–85
- fibroepithelial polyp
 penis, 374
 vulva, 374
- fibromas
 ovary, 114
 testis, 114
- fibromatosis
 ovary, 17–19
- fibrous pseudotumor
 testis, 42
- fixed drug eruption
 penis, 343–44
- flat and papillary urothelial hyperplasia
 bladder, 254–55
- flat condyloma
 vulva, 348
- focal orchitis, 33
- follicle cyst
 ovary, 14
- follicular cells, 7
 embryonic development, 6
- foreign-body granulomas
 ovary, 14
- Frasier syndrome, 52
- frozen sections
 use in prostate and breast cancers, 166–67
- fungal orchio-epididymitis, 36
- gametogenesis, 4
- Gardner–Silengo–Wachtel syndrome, 52
- Gartner duct cysts, 132–33
 vulva, 373
- gastrulation, 3
- genital drafts, 4
- genital herpes
 penis, 341
- genital melanosis
 penis, 381
 vulva, 381
- genital ridges, 4
- genital swellings (embryonic), 5
- genital tract
 embryonic development, 5
- genital tubercle, 5
- genital warts
 penis, 341, 375–76
 vulva, 346–48, 375–76
- genito-palato-cardiac syndrome, 52
- genitourinary system
 metastases to, 408
- genitourinary tract
 endocervicosis, 306–7
 endosalpingiosis, 306–7
- germ cell neoplasia in situ, 26
 ovary, 90–91
 testis, 25–26, 90–91
- germ cell tumors
 definition, 84
 granulomatous vasculitis associated with (testis), 31–32
- germ cell tumors (ovary and testis)
 choriocarcinoma, 95–98
 classification, 84
 dermoid cysts. *See* teratomas
 dysgerminoma (ovary), 91–93
 embryonal carcinoma, 93
 epidermoid cysts. *See* teratomas
 germ cell neoplasia in situ, 90–91
 germinoma, 90–91
 gonadoblastoma, 101
 incidence, 85
 mixed germ cell and sex cord–stromal tumors, 101
 mixed germ cell tumors, 98–99
 mixed teratoma and yolk sac tumor (prepubertal type), 100–1
 origins of, 85–86
 polyembryoma, 98
 regressed (burned out) tumors, 99
 seminoma (testis), 91–93
 spermatocytic tumor, 99
struma ovarii, 90
 teratomas, 86–90

Index

- germ cell tumors (cont.)
 trophoblastic neoplasia, 95–98
 tumors unrelated to germ cell neoplasia in situ, 99
 yolk sac tumor (postpubertal type), 94–95
 yolk sac tumor (prepubertal type), 99–100
- germinoma
 ovary and testis, 90–91
- giant cell arteritis
 testis, 32
- giant multilocular cystadenoma (GMC), 133
- Gilbert–Dreyfus syndrome, 58
- gonadal blastema persistence
 testis, 27
- gonadal cords, 4
- gonadal drafts, 4
- gonadal stromal tumors, 114–17
- gonadoblastoma, 101
 ovary, 117–18
 testis, 26, 117–18
- Gonococci*, 32
- gonorrhea, 132
 penis, 339
- Gorlin syndrome, 114
- granulomatous infections
 ovary, 13–14
- granulomatous orchio-epididymitis, 35–37
- granulomatous tubulitis
 testis, 36–37
- granulomatous vasculitis associated with germ cell tumors
 testis, 31–32
- granulosa cell tumors
 ovary, 111–13
 testis, 111–13
- Graves disease, 52
- growth factors
 role in embryonic development, 5
- gynecologic tract
 carcinomas with micropapillary features, 278–80
 cervical clear cell carcinoma, 184
 clear cell tumors, 179–86
 criteria for malignancy, 208
 mesenchymal tumors, 203
 mesenchymal tumors compared with kidney tumors, 210–11
 metastases to, 397–402
 mixed epithelial and stromal tumors, 191–92
 non-cystic glandular tumors of urachus and gynecologic tract compared, 325
 non-glandular tumors of urachus and gynecologic tract compared, 327–28
 squamotransitional tumors, 274
 transitional cell tumors, 274–75
 urachal and gynecologic tract tumors compared, 316
- Haemophilus ducreyi*, 339
- Hailey–Hailey disease
 vulva, 337
- HAIR-AN syndrome, 17
- hamartomatous lesions
 testis, 24–27
- Hashimoto's thyroiditis, 21
- hemangioma
 kidney, 208–9
 penis, 379
 vulva, 379
- hematocele
 testis, 37
- hematoma
 testis, 37
- Henoch–Schonlein purpura
 testis, 31
- hepatic ectopia, 29
- hepatotesticular fusion, 29
- herpes simplex virus (HSV)
 genital herpes, 341
- hidradenoma papilliferum
 vulva, 378–79
- high-grade endometrial stromal sarcoma
 uterus, 218–20
- high-grade papillary carcinoma, 260
- high-grade prostatic intraepithelial neoplasia (HGPIN), 157
 prostatic utricle, 124
- high-grade serous carcinoma
 ovary, 183–84
- high-grade squamous intraepithelial lesion (HSIL) of the vulva, 179
- hilus cell hyperplasia
 ovary, 19
- hilus cell tumor
 ovary, 17
- hirsuties papillaris penis, 344
- histiocytosis secondary to HES plasma expander
 testis, 35
- histoplasmosis, 36
- HIV patients
 syphilitic orchitis, 36
- hormones
 role in embryonic development, 5
- human papillomavirus (HPV), 240, 274
 genital warts, 341
 HPV-related penile intraepithelial neoplasia, 354–56
 urethral lesions related to, 289
- hyperandrogenism
 in PCOD, 16
- hyperestrogenism, 16
- hypergonadotropic hypogonadism
 female, 21–22
- hyperplasia of the rete testis with hyaline globules, 21–22
- hyperprolactinemia, 16
- hyperreactio luteinalis
 ovary, 19–20
- hypogonadism
 female, 21–22
- hypogonadotropic hypogonadism
 ovary, 21
- hypoplastic zone
 testis, 25–26
- idiopathic granulomatous orchitis (IGO), 36–37
- IgG4-positive orchitis, 34
- IgG4-related diseases, 42
- indifferent embryonic development, 4–5
- infarction
 ovary, 22
- infiltrating urothelial carcinomas
 bladder, 262–69
- inflammatory diseases
 ovary, 13–14
- inflammatory myofibroblastic tumor
 uterus, 224
- inflammatory pathology
 epididymis, 32–37
 testis, 32–37
- intermediate mesoderm, 3
- intersex disorders. *See* disorders of sexual development (DSD)
- interstitial syphilitic orchitis, 33–34
- interstitial tissue, 7
- intraductal carcinoma
 prostate cancer and breast cancer compared, 163–64
- intraductal carcinoma of the prostate (IDC-P), 125
- intraepithelial proliferative lesions
 prostate and breast compared, 157
- intrauterine device (IUD)
 actinomycosis related to, 13
- inverted (endophytic) neoplasms
 bladder, 262
- inverted papilloma of the prostatic urethra, 290
- inverted urothelial papilloma
 bladder, 258–59
- ischemic granulomatous epididymitis, 40–41
- juvenile granulosa cell tumor
 ovary, 184
- juxtaglomerular cell tumor
 kidney, 209
- Kallmann syndrome, 21
- Kaposi sarcoma
 penis, 387–88
 vulva, 387–88
- Kennedy disease, 58
- keratinizing squamous cell metaplasia
 bladder, 276
- kidney
 angiomyolipoma with epithelial cysts (AMLEC), 205–6
 angiomyolipomas, 203–8
 chromophobe renal cell carcinoma with clear cell features, 174
 clear cell renal cell carcinoma, 173
 clear cell papillary renal cell carcinoma (CCPRCC), 176–78
 criteria for malignancy, 208
 cystic nephroma, 189–90
 endometriosis, 306
 epithelioid angiomyolipoma, 179, 206–8
 hemangioma, 208–9
 histologic and immunohistochemical features of clear cell tumors, 179
 intraglomerular lesions, 205
 juxtaglomerular cell tumor, 209
 leiomyoma, 209
 leiomyomatosis and renal cancer syndrome, 217
 lymphangioma, 209
 lymphangiomyomatosis of the renal sinus, 206
 malakoplakia, 179
 mesenchymal tumors, 203–11
 mesenchymal tumors compared with gynecologic tract tumors, 210–11
 microhamartomas, 205
 MiT-associated translocation renal cell carcinoma, 178–79
 mixed epithelial and stromal tumors, 189, 190–92
 multilocular cystic clear cell renal cell neoplasms of low malignant potential (mcCCRCNLMP), 174–76
 neuroendocrine tumors, 238
 oncocyoma-like angiomyolipomas, 206
 papillary renal cell carcinoma with clear cell features, 173–74
 PEComas, 203–8
 renal cell tumors with clear cells, 173–79
 renomedullary interstitial cell tumor, 209
 Schwannoma, 209
 solitary fibrous tumor, 209–10
 urothelial carcinoma, 179
 xanthogranulomatous pyelonephritis, 179
- kidney development
 development of the excretory system, 4
 metanephros (permanent kidney), 4
 movement of the developing kidneys, 4
- Klinefelter syndrome, 28
- Klippel–Trenaunay syndrome, 208
- Kogan disease, 32
- Krukenberg tumor, 18

- labia majora
 embryonic development, 8
- labia minora
 embryonic development, 8
- Laugier–Hunziker syndrome, 381
- leiomyoma
 kidney, 209
 penis, 386
 variants found in the uterus, 213–15
 vulva, 386
- leiomyomatosis and renal cancer syndrome, 217
- leiomyosarcoma
 penis, 386–87
 uterus, 216–17
 vulva, 386–87
- leishmaniasis
 testicular involvement, 36
- LEOPARD syndrome, 381
- leprosy, 14
 testis, 34
- Leydig cell ectopia
 testis, 28
- Leydig cell tumors (ovary and testis), 107–9
- Leydig cells, 5
- lichen planus
 penis, 342–43
 vulva, 336
- lichen sclerosus
 nevi in, 382–83
 penis, 343
 vulva, 334–36
- lichen simplex chronicus
 vulva, 333, 334
- lipid cell tumors
 ovary, 109
- lipomembranous fat necrosis, 30
- liposarcoma
 uterus, 225
- loop of Henle, 4
- low-grade endometrial stromal sarcoma
 uterus, 217–18
- low-grade papillary carcinoma
 bladder, 260
- low-grade squamous intraepithelial lesion (LSIL)
 of the vulva, 348
- Lubs syndrome, 58
- lymphangioma
 kidney, 209
- lymphangioma circumscriptum
 penis, 379–80
 vulva, 379–80
- lymphangiomyomatosis of the renal sinus, 206
- lymphocytic orchitis, 33
- lymphogranuloma venereum
 penis, 340
- lymphoma-like lesion
 cervix, 225
- lymphoma-like orchitis
 testis, 29
- lymphoproliferative disorders
 urethra, 294
- major calix, 4
- malakoplakia, 14
 epididymis, 34
 kidney, 179
 testis, 34
 urethra, 290
- malaria
 testicular involvement, 36
- male sexual differentiation, 5–6
 chronology of main stages of development, 8
 development of the external genitalia, 6
 development of the male genital tract, 5–6
 fate of indifferent drafts, 7
- malignant mixed Müllerian tumors (MMMT)
 ovary, 200–1
 uterus, 198–99
- malignant neoplasms
 penis, 358–70
 vulva, 358–70
- massive edema
 ovary, 17–19
- meconial periorchitis, 37–38
- meconial vaginitis
 testis, 37–38
- median raphe cysts
 penis, 373
- Meigs syndrome, 114, 115
- melanocytic lesions
 penis, 381–83
 vulva, 381–83
- melanocytic nevi of genital type
 penis, 382
 vulva, 382
- melanoma
 penis, 368–70
 urethra (female), 294
 urethra (male), 301
 vulva, 368–70
- menopause, 8
 premature, 21
- Merkel cell carcinoma
 penis, 365–67
 vulva, 365–67
- mesenchymal tumors
 cervix, 225
 comparison of gynecologic tract and kidney tumors, 210–11
 gynecologic tract, 203
 kidney, 203–11
 ovary, 228
 penis, 385–88
 prostate and breast compared, 164–66
 urethra, 294
 uterus, 213–25
 vagina, 225–28
 vulva, 225–28, 385–88
- mesonephric ducts, 4, 5
- mesonephric remnants
 description, 150
 epoophoron, 150
 gynecologic tract, 150–52
 hyperplasia of prostate mesonephric remnants of the prostate, 152–53
 mesonephric carcinoma in females, 151–52
 mesonephric hyperplasia in females, 150–52
 paroophoron, 150
- mesonephric tubules, 4
- mesonephros, 3, 4, 5
- mesothelial cysts
 testis, 41
- mesothelioma
 testis, 38
- metanephric mass, 4
- metanephros (permanent kidney), 3, 4
- metastases
 ovary, 184
 prostate and breast compared, 164–66
 to the genitourinary system, 408
 to the gynecologic tract, 397–402
- micaceous balanitis, 343
- microhamartomas
 kidney, 205
- micropapillary carcinomas
 differential diagnosis, 278–80
- micropapillary urothelial carcinoma
 bladder, 278–80
- minor calix, 4
- Mit-associated translocation renal cell carcinoma, 178–79
- mitochondrial myopathy, 25
- mixed epithelial and mesenchymal tumors
 uterus, 194–99
- mixed epithelial and stromal tumors (MEST)
 comparison between gynecologic tract and kidney tumors, 191–92
 gynecologic tract, 191–92
 kidney, 189, 190–92
 ovary, 200–2
 seminal vesicles, 135–36, 143–44
- mixed germ cell and sex cord–stromal tumors, 101
- mixed sex cord–stromal tumors, 109–11
- mixed teratoma and yolk sac tumor (prepubertal type), 100–1
- molluscipoxvirus, 341
- molluscum contagiosum
 penis, 341
- morbid obesity, 21
- mucinous adenocarcinoma
 urethra (female), 294
 urethra (male), 296–301
- mucinous cystic tumors
 ovary, 319–22
 urachus, 316–17
 urachus compared with ovary, 322
- mucosal melanotic macule
 penis, 381
 vulva, 381
- mucous membrane pemphigoid
 vulva, 336
- Muir–Torre syndrome, 377
- Müllerian adenocarcinomas
 ovary, 201–2
- Müllerian cysts
 female, 132
 vulva, 373
- Müllerian duct cyst
 male, 129
- Müllerian ducts, 8
 embryonic development, 5
- Müllerian lesions
 bladder, 304–7
- Müllerianosis
 definition, 304
 urinary tract, 304
- multilocular cystic clear cell renal cell neoplasms of low malignant potential (mcCCRCNLMP), 174–76
- multiple enchondromatosis, 111
- multiple pterygium syndrome, 52
- Mycoplasma genitalium*, 32
- Mycoplasma hominis*, 13
- myofibroblastic lesions
 penis, 383–85
 vulva, 383–85
- Neisseria gonorrhoeae*, 13, 339
- Nelson syndrome, 29
- nephrogenic adenoma
 mimicked by clear cell carcinoma of the bladder, 313–14
 urethra, 288–89
- nephrogenic cords, 3–4
- nephrons
 embryonic development, 4
- neuroendocrine carcinoma
 urachus, 327
- neuroendocrine tumors
 bladder, 233–35
 cervix, 238–40
 classification, 233
 comparison of male and female genital tracts and urinary tract, 243
 diagnostic criteria, 233

Index

- neuroendocrine tumors (cont.)
 endometrium, 240–41
 kidney, 238
 origin of, 233
 ovary, 241–42
 prostate, 235–38
 ureters, 238
 uterus, 240–41
- nevi in lichen sclerosus
 penis, 382–83
 vulva, 382–83
- nevus lipomatosus superficialis of Zurhelle, 374
- non-cystic glandular tumors
 urachus, 322–25
 urachus and gynecologic tract compared, 325
- non-glandular tumors
 urachus, 326–27
 urachus and gynecologic tract compared, 327–28
- non-granulomatous infectious diseases
 ovary, 13
- non-granulomatous orchio-epididymitis, 32–35
- non-neoplastic lesions
 ovary, 13–22
 testis, 24–43
- Noonan syndrome, 25
- Ollier disease, 111
- oncocyoma-like angiomyolipomas
 kidney, 206
- oogonia, 7
- embryonic development, 4
- orchio-epididymitis
 granulomatous, 35–37
 non-granulomatous, 32–35
- organ of Rosenmüller, 150
- osseous heterotopia, 29
- ovarian epithelial tumors
 Brenner tumors, 79
 clear cell tumors, 77–78
 endometrioid tumors, 75–77
 features of, 62
 mucinous tumors, 73–75
 origins of, 62–64
 seromucinous tumors, 79–80
 serous tumors, 64–73
 undifferentiated carcinoma, 80
- ovarian remnant syndrome, 15–16
- ovarian sex cord–stromal tumors
 features of, 103
 fibromas, 114
 gonadal stromal tumors, 114–17
 gonadoblastoma, 117–18
 granulosa cell tumors, 111–13
 Leydig cell tumors, 107–9
 lipid cell tumors, 109
 mixed germ cell and sex cord–stromal tumors,
 117–18
 mixed sex cord–stromal tumors, 109–11
 Sertoli cell tumors, 103–7
 Sertoli–Leydig cell tumors (SLCTs), 109–11
 sex cord tumor with annular tubules, 107
 steroid cell tumors, 109
 thecomas, 114–17
 types of, 103
 unclassified mixed germ cell sex cord–stromal
 tumors, 118
 unclassified sex cord–stromal tumors, 117
- ovarian surface epithelium, 8
- ovary
 actinomycosis related to IUD, 13
 autoimmune oophoritis, 21–22
 Brenner tumor, 247–48
 Brenner tumor (borderline), 248–51
 Brenner tumor (malignant), 248–51
 carcinosarcoma, 200–1
 chemotherapy effects, 22
- clear cell carcinoma, 181–83, 184
- clear cell carcinoma compared in urinary tract
 and ovary, 310–14
- clear cell tumors, 181–84
- combined sarcoma and epithelial tumor, 202
- congenital lesions, 22
- corpus luteum cyst, 15
- cytomegalovirus oophoritis, 13
- differentiation of the indifferent gonad, 5
- dysgerminoma, 184
- ectopic decidua, 20–21
- embryonic development, 6–8
- endometrioid carcinoma, 184
- fibromatosis, 17–19
- follicle cyst, 14
- foreign-body granulomas, 14
- fungal infections, 13
- granulomatous infections, 13–14
- high-grade serous carcinoma, 183–84
- hilus cell hyperplasia, 19
- hilus cell tumor, 17
- hypergonadotropic hypogonadism, 21–22
- hyperreactio luteinalis, 19–20
- hypogonadism, 21–22
- hypogonadotropic hypogonadism, 21
- infarction, 22
- inflammatory diseases, 13–14
- juvenile granulosa cell tumor, 184
- malignant mixed Müllerian tumors (MMMT),
 200–1
- massive edema, 17–19
- mesenchymal tumors, 228
- metastases, 184
- mixed epithelial and stromal tumors, 200–2
- mucinous cystic tumors, 319–22
- mucinous cystic tumors of ovary and urachus
 compared, 322
- Müllerian adenosarcomas, 201–2
- neuroendocrine tumors, 241–42
- non-granulomatous infectious diseases, 13
- non-infectious granulomas, 14
- non-neoplastic lesions, 13–22
- ovarian abscesses, 13
- ovarian myxoma, 18
- ovarian remnant syndrome, 15–16
- polycystic ovarian disease (PCOD), 16
- pregnancy luteoma, 19
- pregnancy-related lesions, 19–21
- premature menopause, 21
- premature ovarian failure, 21–22
- radiotherapy effects, 22
- resistant ovary syndrome, 21
- solitary cysts, 14–15
- stromal hyperplasia, 17
- stromal hyperthecosis, 17
- stromal luteoma, 17
- torsion, 22
- transitional cell carcinoma, 251–52
- transitional cell tumor pathogenesis, 247
- transitional cell tumors, 247–52
- tubo-ovarian abscesses, 13
- types of non-neoplastic lesions, 13
- uterus-like ovarian mass, 22
- Wolffian tumor, 151–52
- yolk sac tumor, 184
- oviducts
 embryonic development, 8
- ovotestes, 27, 49–50
- Paget disease, 257
 penis, 356
- papillary renal cell carcinoma with clear cell
 features, 173–74
- papillary urothelial neoplasm of low malignant
 potential (PUNLMP)
 bladder, 259–60
- Paracoccidioides brasiliensis*, 36
- paraganglioma
 bladder, 233–34
- paramesonephric duct, 5
- paraovarium, 150
- parasites
 orchitis caused by, 36
- parasitic cysts of the prostate, 130
- paratesticular cysts, 41–42
- paroophoron, 150
- pearly penile papules, 344
- PEComas. *See* perivascular epithelioid tumors
- Pediculus pubis* (pubic lice), 341
- pelvic inflammatory disease (PID), 13
- pelvic tuberculosis, 13
- pemphigus vulgaris
 vulva, 336
- penile intraepithelial neoplasia (PeIN)
 basaloid PeIN, 354–56
 classification, 354
 differentiated PeIN, 354
 HPV-related PeIN, 354–56
 presentation, 354
 terms used for, 354
 warty PeIN, 354–56
- penile urethra
 embryonic development, 4, 5, 6
- penis
 adnexal lesions, 377–79
 aggressive angiomyxoma, 383
 allergic eczema, 343
 angiokeratoma, 344, 380
 angiomyofibroblastoma, 383–85
 anogenital mammary-like gland lesions, 377–79
 bacterial infections, 339–40
 balanitis circinata, 340
 balanitis xerotica obliterans, 343
 Bartholin gland carcinoma, 367–68
 basal cell carcinoma, 363–64
 benign vascular lesions, 379–80
 Bowen disease, 354
 candidiasis, 339
 cellular angiofibroma, 385
 chancroid, 339
 classification of dermatoses, 339
 complex anatomy, 373
 condyloma acuminata, 375–76
 cystic lesions, 373
 embryonic development, 6
 epithelial lesions, 374–76
 erythroplasia of Queyrat, 354
 extramammary Paget disease, 356, 364–65
 fibroepithelial polyp, 374
 fixed drug eruption, 343–44
 genital herpes, 341
 genital melanosis, 381
 genital warts, 341, 375–76
 gonorrhea, 339
 hemangioma, 379
 herpes simplex virus (HSV) infection, 341
 hirsuties papillaris penis, 344
 human papillomavirus (HPV) infection, 341
 infective diseases, 339–41
 infestations, 340–41
 inflammatory diseases, 341–44
 intraepithelial lesions, 354–56
 intraepithelial lesions of vulva and penis
 compared, 356
 Kaposi sarcoma, 387–88
 leiomyoma, 386
 leiomyosarcoma, 386–87
 lichen planus, 342–43
 lichen sclerosus, 343
 lymphangioma circumscriptum, 379–80
 lymphogranuloma venereum, 340
 malignant neoplasms, 358–70

- median raphe cysts, 373
 melanocytic lesions, 381–83
 melanocytic nevi of genital type, 382
 melanoma, 368–70
 Merkel cell carcinoma, 365–67
 mesenchymal tumors, 385–88
 micaceous balanitis, 343
 molluscum contagiosum, 341
 mucosal melanotic macule, 381
 mycotic infections, 339
 myofibroblastic/fibroblastic lesions, 383–85
 nevi in lichen sclerosus, 382–83
 origins of malignant neoplasms, 358
 Paget disease, 356
 pearly penile papules, 344
 pediculosis pubis (pubic lice), 341
 psoriasis, 342
 Reiter syndrome, 340
 scabies, 340
 seborrheic keratosis, 375
 smooth muscle neoplasms, 385–87
 soft chancre, 339
 squamous cell carcinoma, 358–63
 superficial angiomyxoma, 385
 syphilis, 339
 syringoma, 379
 viral infections, 341
 Zoon's balanitis, 344
- perineum
 embryonic development, 5
 peritumoral granulomatous orchitis, 36–37
 periurethral prostatic ducts
 features of, 124–25
 intraductal carcinoma of the prostate (IDC-P), 125
 neoplasms, 124–25
 prostatic ductal adenocarcinoma, 125–26
 perivascular epithelioid cell (PEC), 203
 perivascular epithelioid tumors (PEComas)
 kidney, 203–8
 uterus, 221–24
 Peutz–Jeghers syndrome, 26, 103, 106, 107, 381
 phyllodes-type tumors
 prostate, 134–35
 Pick's adenoma
 testis, 25–26
 plasma cell granuloma of the testis, 34
 plasma cell vulvitis, 337
 polyarteritis nodosa (PAN)
 testis, 31
 polycystic ovarian disease (PCOD), 16
 polyembryoma
 ovary and testis, 98
 polypoid intestinal metaplasia
 urethra, 290
 polypoid nodular calcifying proliferation of the
 rete testis, 40
 polypoid urethritis, 288
 postoperative spindle cell nodule
 cervix, 225
 pregnancy luteoma
 ovary, 19
 pregnancy-related lesions of the ovary, 19–21
 primary autoimmune orchitis, 33
 primary oocytes
 embryonic development, 7
 primitive neuroectodermal tumors (PNET)
 uterus, 224
 primordial follicles, 7
 primordial germ cells, 4, 5
 development of primary oocytes, 7
 pronephric ducts, 4
 pronephros, 3, 4
 prostate
 benign epithelial proliferations, 157
 benign prostatic hyperplasia (BPH), 130, 157
 biphasic tumors, 140–43
 ectopic prostatic tissue, 145–48
 embryonic development, 6
 female homologs of the prostate and associated
 structures, 131–32
 histology compared to the breast, 155–57
 hyperplasia of mesonephric remnants, 152–53
 intraepithelial proliferative lesions, 157
 involvement in bladder cancer, 272
 microscopic anatomy compared to the breast, 155
 neuroendocrine tumors, 235–38
 prostatic intraepithelial neoplasia (PIN), 157
 sarcomatoid carcinoma (carcinosarcoma), 143
 similarities and differences to the breast, 157
 specimen handling compared to breast
 specimens, 167–68
 stromal sarcoma, 140–43
 STUMP, 140–43
 prostate cancer
 genetic changes compared with breast cancer,
 166
 Gleason grading system, 161–63
 grading compared to breast cancer, 161–63
 histologic variants compared with breast
 cancer, 164
 intraductal carcinoma, 163–64
 intraductal carcinoma of the prostate (IDC-P),
 125
 mesenchymal tumors, 164–66
 metastatic tumors, 164–66
 pathologic features compared to breast cancer,
 158–61
 prostatic ductal adenocarcinoma, 125–26
 research work of the Ancona group, 123
 rhabdomyosarcoma, 164
 treatment compared with breast cancer, 167
 use of frozen sections, 166–67
 prostate cysts
 classification, 129
 complicated cysts, 130
 cystadenocarcinoma, 133–34
 cystic dilation of prostatic utricle, 129
 ejaculatory duct cysts, 129
 enlarged prostatic utricle, 129
 features of prostate and surrounding area cystic
 lesions, 128–29
 giant multilocular cystadenoma (GMC), 133
 intraparenchymal cysts, 130
 isolated medial cysts, 129
 Müllerian duct cyst, 129
 multiple cysts, 130
 neoplastic cysts, 133–35
 non-neoplastic cysts, 129–30
 parasitic cysts, 130
 phyllodes-type tumors, 134–35
 prostatic utricle cyst, 129
 pseudocystic prostate carcinoma, 135
 simple cysts (simple retention cysts), 130
 stromal tumor with phyllodes-type growth,
 134–35
 prostate tumors
 stromal sarcoma, 164–65
 stromal tumor of uncertain malignant potential
 (STUMP), 164–65
 prostatic ductal adenocarcinoma, 125–26
 prostatic urethra
 embryonic development, 5
 prostatic utricle
 abnormalities, 124
 anatomic location, 123
 cystic dilatation of, 129
 embryonic development, 123–24
 enlarged, 129
 epithelial metaplasias, 124
 high-grade prostatic intraepithelial neoplasia
 (HGPIN), 124
 utricle cyst (cystic utricle), 124
 vagina masculinus (male vagina), 124
 prostatic utricle cyst, 129
 proximal convoluted tubule, 4
 pseudocystic prostate carcinoma, 135
 pseudosarcomatous periorchitis
 testis, 29
 psoriasis
 penis, 342
 vulva, 334
- radiotherapy
 effects on the ovary, 22
 reactive hyperplasia of the rete testis, 40
 reactive mesothelial hyperplasia (RMH)
 testis, 21
 Reifenstein syndrome, 58
 Reiter syndrome
 penis, 340
 relapsing polychondritis, 32
 renal blastema ectopia, 29
 renal pelvis, 4
 renomedullary interstitial cell tumor, 209
 resistant ovary syndrome, 21
 rete ovarii, 7
 rete testis, 5
 acquired pathology, 39–40
 adenomatous hyperplasia, 39–40
 cystic dysplasia, 24–25
 cystic transformation, 39
 hyperplasia with hyaline globules, 21–22
 polypoid nodular calcifying proliferation, 40
 reactive hyperplasia, 40
 rhabdomyosarcoma
 prostate, 164
 uterus, 224–25
 rheumatoid arthritis, 32
 Rosai–Dorfman disease
 testis, 34
 Rossewater syndrome, 58
 RSPO1 gene, 5
- salpingitis, 13
 sarcoidosis, 14
 epididymis, 36
 testis, 36
 sarcomatoid carcinoma
 prostate, 143
Sarcoptes scabiei var. *hominis*, 340
 scabies
 penis, 340
 schistosomiasis, 13
 testicular involvement, 36
 Schwannoma
 kidney, 209
 sclerosing lipogranuloma
 testis, 42–43
 sclerosing peritonitis, 18
 sclerosing stromal tumor, 18
 scrotum
 embryonic development, 6
 seborrheic keratosis
 penis, 375
 vulva, 375
 secondary tumors. *See* metastases
 segmental testicular infarction, 30
 seminal vesicle cysts
 neoplastic cysts, 135–37
 non-neoplastic cysts, 130–31
 seminal vesicles
 adenocarcinoma, 136–37
 biphasic tumors, 143–44
 cystadenoma, 135–36
 embryonic development, 4, 5
 mixed epithelial and stromal tumors, 135–36,
 143–44

Index

- seminiferous cords, 5
 seminiferous tubule ectopia
 testis, 27–28
 seminiferous tubules, 5
 seminoma
 testis, 91–93
 Sertoli cell hyperplasia
 testis, 25–26
 Sertoli cell nodule
 testis, 25–26
 Sertoli cell tumors
 ovary and testis, 103–7
 Sertoli cells, 5
 Sertoli–Leydig cell hamartoma
 testis, 26
 Sertoli–Leydig cell tumors (SLCTs), 109–11
 sex cord stromal tumors (ovary and testis)
 features of, 103
 fibromas, 114
 gonadal stromal tumors, 114–17
 gonadoblastoma, 117–18
 granulosa cell tumors, 111–13
 Leydig cell tumors, 107–9
 lipid cell tumors, 109
 mixed germ cell and sex cord–stromal tumors,
 117–18
 mixed sex cord–stromal tumors, 109–11
 Sertoli cell tumors, 103–7
 Sertoli–Leydig cell tumors (SLCTs), 109–11
 sex-cord tumor with annular tubules, 107
 steroid cell tumors, 109
 thecomas, 114–17
 types of, 103
 unclassified mixed germ cell sex cord–stromal
 tumors, 118
 unclassified sex cord–stromal tumors, 117
 sex cord–tumor with annular tubules
 ovary and testis, 107
 sexual development. *See* Disorders of sexual
 development (DSD)
Sfl gene, 4, 5
 Skene duct cysts, 132
 female urethra, 289
 vulva, 373
 skenitis, 132
 smooth muscle hamartoma
 testis, 27
 smooth muscle neoplasms
 penis, 385–87
 vulva, 385–87
 smooth muscle tumor of uncertain malignant
 potential (STUMP)
 uterus, 215–16
 smooth muscle tumors
 uterus, 213–17
 soft chancre
 penis, 339
 Sohval syndrome, 53–54
 solitary fibrous tumor
 kidney, 209–10
SOX9 gene, 5
 specimen handling
 prostate and breast specimens compared,
 167–68
 sperm granuloma, 41
 spermatocele
 testis, 41–42
 spermatocytic tumor, 99
 spermatogonia, 5
 embryonic development, 4
 splanchnopleura, 4
 splenic ectopia, 29
 splenogonadal fusion, 29
Sporothrix schenckii, 36
 squamotransitional tumors
 gynecologic tract, 274
 squamous cell carcinoma
 bladder, 275–76
 penis, 358–63
 urachus, 327
 urethra (female), 290
 urethra (male), 295–96
 vulva, 358–63
 vulvar squamous cell carcinoma (VSCC)
 development, 346
 squamous cell metaplasia
 bladder, 276
 squamous cell papilloma
 bladder, 277
 squamous cell tumors and lesions
 urinary tract, 275–77
 squamous papilloma
 cervix, 274
 urethra, 290
SRY gene, 5
Staphylococcus aureus infection, 131
 Stein–Leventhal syndrome, 16
 steroid cell tumors
 ovary, 109
 stromal hyperplasia
 ovary, 17
 stromal hyperthecosis
 ovary, 17
 stromal luteoma
 ovary, 17
 stromal sarcoma
 prostate, 140–43, 164–65
 stromal tumor of uncertain malignant potential
 (STUMP)
 prostate, 140–43, 164–65
 stromal tumor with phyllodes-type growth
 prostate, 134–35
struma ovarii, 90
 Sturge–Weber syndrome, 208
 superficial angiomyxoma
 penis, 385
 vulva, 385
 superficial myofibroblastoma
 vagina, 227–28
 vulva, 227–28
 Swyer syndrome, 51–52, 117
 syphilis, 14
 penis, 339
 syphilitic orchitis
 congenital and acquired forms, 35–36
 syringocele, 131
 male urethra, 289
 syringoma
 penis, 379
 vulva, 379
 systemic angiomatosis, 208
TDF gene, 5
 teratomas
 ectopic prostatic tissue, 145
 ovary and testis, 86–90
 testicular epithelial neoplasms
 Brenner tumors, 79
 clear cell tumors, 78
 endometrioid tumors, 77
 mucinous tumors, 73–75
 origins of, 62–64
 ovarian epithelial-type tumors, 62
 seromucinous tumors, 79–80
 serous tumors, 64–73
 testicular hemorrhagic infarction, 29
 testicular pseudolymphoma, 33
 testicular sex cord–stromal tumors
 features of, 103
 fibromas, 114
 gonadal stromal tumors, 114–17
 gonadoblastoma, 117–18
 granulosa cell tumors, 111–13
 Leydig cell tumors, 107–9
 mixed germ cell and sex cord–stromal tumors,
 117–18
 mixed sex cord–stromal tumors, 109–11
 Sertoli cell tumors, 103–7
 Sertoli–Leydig cell tumors (SLCTs), 109–11
 sex cord tumor with annular tubules, 107
 thecomas, 114–17
 types of, 103
 unclassified mixed germ cell sex cord–stromal
 tumors, 118
 unclassified sex cord–stromal tumors, 117
 testis
 acquired pathology of the rete testis, 39–40
 acute orchio-epididymitis, 32–33
 adenomatous hyperplasia of the rete testis,
 39–40
 adrenal cortical ectopia, 28–29
 androgen insensitivity syndrome (AIS), 26
 brucellosis, 36
 ceroid granuloma of the testis and epididymis,
 34
 cholesterol granulomas, 41
 chronic non-specific orchitis, 33
 congenital testicular lymphangiectasis, 26–27
 cryptorchidism, 24, 25
 cystic dysplasia of the epididymis, 25
 cystic dysplasia of the rete testis, 24–25
 cystic transformation of the rete testis, 39
 differentiation of the indifferent gonad, 5
 ectopias, 27–29
 endometriosis, 41
 epididymitis nodosa, 41
 Erdheim–Chester disease, 34–35
 fetal gonadoblastoid testicular dysplasia
 (FTGD), 25
 fibrous pseudotumor, 42
 focal orchitis, 33
 fungal orchio-epididymitis, 36
 germ cell neoplasia in situ, 25–26
 giant cell arteritis, 32
 gonadoblastoma, 26
 granulomatous orchio-epididymitis, 35–37
 granulomatous tubulitis, 36–37
 granulomatous vasculitis associated with germ
 cell tumors, 31–32
 hamartomatous lesions, 24–27
 hematocele, 37
 hematoma, 37
 Henoch–Schönlein purpura, 31
 histiocytosis secondary to HES plasma
 expander, 35
 hyperplasia of the rete testis with hyaline
 globules, 40
 hypoplastic zone, 25–26
 idiopathic granulomatous orchitis (IGO), 36–37
 IgG4-positive orchitis, 34
 inflammatory pathology, 32–37
 interstitial syphilitic orchitis, 33–34
 ischemic granulomatous epididymitis, 40–41
 isolated arteritis of the testis and epididymis, 31
 leprosy, 34
 Leydig cell ectopia, 28
 lymphocytic orchitis, 33
 lymphoma-like orchitis, 29
 malakoplakia, 34
 meconial periorchitis, 37–38
 meconial vaginalitis, 37–38
 mesothelial cysts, 41
 mesothelioma, 38
 movement from to the scrotum, 5
 non-granulomatous orchio-epididymitis, 32–35
 non-neoplastic lesions, 24–43
 orchitis caused by parasites, 36
 paratesticular cysts, 41–42

- paratesticular tumor-like lesions, 40–43
 pathology of the vaginal cavity, 37–38
 peritumoral granulomatous orchitis, 36–37
 persistent gonadal blastema, 27
 Pick's adenoma, 25–26
 plasma cell granuloma of the testis, 34
 polyarteritis nodosa (PAN), 31
 polypoid nodular calcifying proliferation of the rete testis, 40
 primary autoimmune orchitis, 33
 pseudosarcomatous periorchitis, 29
 reactive hyperplasia of the rete testis, 40
 reactive mesothelial hyperplasia (RMH), 38
 Rosai–Dorfman disease, 34
 sarcoidosis, 36
 schistosomiasis, 36
 sclerosing lipogranuloma, 42–43
 segmental testicular infarction, 33
 seminiferous tubule ectopia, 27–28
 Sertoli cell hyperplasia, 25–26
 Sertoli cell nodule, 25–26
 Sertoli–Leydig cell hamartoma, 26
 smooth muscle hamartoma, 27
 sperm granuloma, 41
 spermatocele, 41–42
 syphilitic orchitis (congenital and acquired forms), 35–36
 testicular dysgenesis syndrome, 25
 testicular hemorrhagic infarction, 29
 testicular pseudolymphoma, 33
 thromboangiitis obliterans, 32
 torsion, 29–30
 tuberculosis, 35
 tubular hamartoma, 26
 varicocele, 30–31
 vascular pathology, 29–32
 vasculitis, 31–32
 vasitis, 41
 Wegener's granulomatosis, 31
 Whipple disease, 34
 xanthogranulomatous orchio-epididymitis, 34–35
- testosterone, 5
- thecomas
 ovary, 114–17
 testis, 114–17
- thromboangiitis obliterans
 testis, 32
- torsion
 ovary, 22
 testicle, 29–30
- torulopsis, 36
- toxoplasmosis
 testicular involvement, 36
- transitional cell carcinoma
 ovary, 251–52
- transitional cell metaplasia
 cervix, 274
 vagina, 274
- transitional cell tumors
 bladder, 254–72
 gynecologic tract, 274–75
 ovary, 247–52
- Treponema pallidum*, 36, 339
- Tropheryma whipplei*, 34
- trophoblastic neoplasia
 ovary and testis, 95–98
- trypanosomiasis
 testicular involvement, 36
- tuberculosis
 epididymis, 35
 testis, 35
- tubular hamartoma
 testis, 26
- tunica albuginea, 5
- Turner syndrome, 50–51
- undifferentiated sarcoma
 uterus, 220–21
- urachus
 adenocarcinoma, 323–25
 classification of epithelial neoplasms, 316
 mucinous cystic tumors, 316–17
 mucinous cystic tumors of urachus and ovary compared, 322
 neuroendocrine carcinoma, 327
 non-cystic glandular tumors, 322–25
 non-cystic glandular tumors of urachus and gynecologic tract compared, 325
 non-glandular tumors, 326–27
 non-glandular tumors of urachus and gynecologic tract compared, 327–28
 squamous cell carcinoma, 327
 urachal and gynecologic tract tumors compared, 316
 urothelial carcinoma, 326–27
 villous adenoma, 322–23
- Ureaplasma urealyticum*, 32
- ureteric bud, 4
- ureters
 embryonic development, 4
 endometriosis, 305–6
 malignancy arising from endometriosis, 306
 neuroendocrine tumors, 238
- urethra
 adenocarcinoma (female), 291
 adenocarcinoma (male), 296–301
 benign tumors, 290
 caruncle, 287
 clear cell adenocarcinoma (female), 291–94
 clear cell adenocarcinoma (male), 301
 Cowper glands-associated lesions, 289
 description, 285
 diverticula, 287
 embryonic development, 4
 endometriosis, 290, 306
 female anatomy and histology, 285
 human papillomavirus (HPV)-related lesion, 289
 inflammation and pseudotumor lesions, 287–90
 inverted papilloma of the prostatic urethra, 290
 lymphoproliferative disorders, 294
 malakoplakia, 290
 male anatomy and histology, 285–87
 malignant tumors (female), 290–94
 malignant tumors (male), 294–302
 melanoma (female), 294
 melanoma (male), 301
 mesenchymal tumors, 294
 mucinous adenocarcinoma (female), 294
 mucinous adenocarcinoma (male), 296–301
 nephrogenic adenoma, 288–89
 polypoid intestinal metaplasia, 290
 polypoid urethritis, 288
 polyps, fibrous type, 288
 polyps, prostatic type, 287
 secondary tumors (female), 294
 secondary tumors (male), 302
 Skene duct cysts, 289
 squamous cell carcinoma (female), 290
 squamous cell carcinoma (male), 295–96
 squamous papilloma, 290
 syringocele (male), 289
 tumors, 290–302
 urothelial carcinoma (female), 290–91
 urothelial carcinoma (male), 296
 urothelial papilloma, 290
 verumontanum mucosal gland hyperplasia, 289
- urethral folds, 5
- urinary system
 components of, 3
 embryonic development, 3–4
- urinary tract
 clear cell carcinoma compared in urinary tract and ovary, 310–14
 endocervicosis, 304
 endometriosis, 304
 endosalpingiosis, 304
 metastases to, 408
 Müllerianosis, 304
 squamous cell tumors and lesions, 275–77
- urogenital membrane, 5
- urogenital sinus, 4, 5, 6
- urogynecologic cysts, 131–33
- urorectal septum, 4
- urothelial carcinoma
 kidney, 179
 urachus, 326–27
 urethra (female), 290–91
 urethra (male), 296
- urothelial carcinoma in situ (CIS)
 bladder, 255–58
- urothelial carcinoma variants
 bladder, 262–69
- urothelial carcinoma with squamous differentiation
 bladder, 275
- urothelial dysplasia
 bladder, 255
- urothelial papilloma
 bladder, 258–59
 urethra, 290
- urothelial proliferation of uncertain malignant potential (UPUMP)
 bladder, 254–55
- uterus
 adenofibroma, 196–97
 adenomyoma, 194–95
 adenosarcoma, 197–98
 alveolar soft part sarcoma, 225
 angiosarcoma, 225
 atypical polypoid adenomyoma (APAM), 195–96
 carcinosarcoma, 198–99
 clear cell carcinomas, 185–86
 embryonic development, 8
 endometrial stromal and related tumors, 217–20
 endometrial stromal nodule, 217–18
 high-grade endometrial stromal sarcoma, 218–20
 immunoreactivity of different mesenchymal tumors, 218
 inflammatory myofibroblastic tumor, 224
 leiomyoma and variants, 213–15
 leiomyomatosis and renal cancer syndrome, 217
 leiomyosarcoma, 216–17
 liposarcoma, 225
 low-grade endometrial stromal sarcoma, 217–18
 malignant mixed Müllerian tumor (MMMT), 198–99
 mesenchymal tumors, 213–25
 mixed epithelial and mesenchymal tumors, 194–99
 neuroendocrine tumors, 240–41
 perivascular epithelioid tumor (PEComa), 221–24
 primitive neuroectodermal tumors (PNET), 224
 rhabdomyosarcoma, 224–25
 smooth muscle tumor of uncertain malignant potential (STUMP), 215–16
 smooth muscle tumors, 213–17
 undifferentiated sarcoma, 220–21
 uterine tumor resembling ovarian sex cord tumor (UTROSCT), 221
 uterus-like ovarian mass, 22

Index

- vagina
 aggressive angiomyxoma, 226–27
 angiofibromyxoma, 225–26
 embryonic development, 8
 mesenchymal tumors, 225–28
 squamotransitional tumors, 274
 superficial myofibroblastoma, 227–28
 transitional cell metaplasia, 274
- vaginal vestibule
 embryonic development, 4, 8
- varicocele
 testis, 30–31
- vas deferens
 embryonic development, 4, 5
- vas deferens cysts, 131
- vascular pathology
 testis, 29–32
- vasculitis
 testis, 31–32
- vasectomy
 sperm granuloma, 41
 vasitis, 41
- vasitis
 testis, 41
- verrucous carcinoma
 bladder, 276–77
- verumontanum, 123
- verumontanum mucosal gland hyperplasia, 289
- villous adenoma
 urachus, 322–23
- vulva
 acantholytic dermatosis of the vulvocruural area, 337
 adnexal lesions, 377–79
 aggressive angiomyxoma, 226–27, 383
 angiokeratoma, 380
 angiofibromyxoma, 225–26, 383–85
 anogenital mammary-like gland lesions, 377–79
 aphthous ulcers, 337
 atopic dermatitis, 333
 Bartholin duct cysts, 373
 Bartholin gland adenoma, 377
 Bartholin gland carcinoma, 367–68
 Bartholin gland cysts, 376
 Bartholin gland hyperplasia, 376–77
 Bartholin gland lesions, 376–77
 basal cell carcinoma, 363–64
 Behçet disease, 337
 benign vascular lesions, 379–80
 Bowen disease, 348
 bowenoid dysplasia, 348
 bullous pemphigoid, 336
 canal of Nuck cysts, 374
 cellular angiofibroma, 385
 classification of intraepithelial lesions, 346–47
 classification of vulvar dermatoses, 333
 complex anatomy, 373
 condyloma acuminata, 346–48, 375–76
 contact dermatitis, 333–34
 Crohn disease, 337
 cystic lesions, 373–74
 Darier disease, 336
 dVIN lesions, 350–52
 eczematous dermatitis, 333
 endometriosis, 380–81
 epidermal inclusion cysts, 374
 epithelial lesions, 374–76
 extramammary Paget disease, 364–65
 fibroepithelial polyp, 374
 flat condyloma, 348
 Gartner duct cysts, 373
 genital melanosis, 381
 genital warts, 346–48, 375–76
 Hailey–Hailey disease, 337
 hemangioma, 379
 hidradenoma papilliferum, 378–79
 high-grade squamous intraepithelial lesions (HSIL), 348–50
 inflammatory lesions with a predominant acanthotic pattern, 334
 inflammatory lesions with a predominant granulomatous pattern, 337
 inflammatory lesions with a predominant spongiotic pattern, 333–34
 inflammatory lesions with a predominant vasculopathic pattern, 337
 inflammatory lesions with a predominant vesiculo-bullous pattern, 336–37
 inflammatory lesions with a predominant lichenoid pattern, 334–36
 intraepithelial lesions, 346–52
 intraepithelial lesions of vulva and penis compared, 356
 intraepithelial neoplasia of differentiated type (dVIN), 350–52
 Kaposi sarcoma, 387–88
 leiomyoma, 386
 leiomyosarcoma, 386–87
 lichen planus, 336
 lichen sclerosus, 334–36
 lichen simplex chronicus, 333, 334
 low-grade squamous intraepithelial lesions (LSIL), 348
 lymphangioma circumscriptum, 379–80
 malignant neoplasms, 358–70
 melanocytic lesions, 381–83
 melanocytic nevi of genital type, 382
 melanoma, 368–70
 Merkel cell carcinoma, 365–67
 mesenchymal tumors, 225–28, 385–88
 mucosal melanotic macule, 381
 mucous membrane pemphigoid, 336
 Müllerian cysts, 373
 myofibroblastic/fibroblastic lesions, 383–85
 nevi in lichen sclerosus, 382–83
 origins of malignant neoplasms, 358
 pemphigus vulgaris, 336
 plasma cell vulvitis, 337
 psoriasis, 334
 seborrheic keratosis, 375
 Skene duct cysts, 373
 smooth muscle neoplasms, 385–87
 squamous cell carcinoma, 358–63
 superficial angiomyxoma, 385
 superficial myofibroblastoma, 227–28
 syringoma, 379
 terminology for intraepithelial lesions, 346–47
 uVIN lesion, 348
 VIN1 lesion, 348
 VIN2–3 lesion, 348
 vulvar squamous cell carcinoma (VSCC) development, 346
 Zoon vulvitis, 337
- Walker–Warburg syndrome, 25
- Wegener’s granulomatosis
 testis, 31
- Whipple disease
 testis, 34
- WNT4* gene, 5
- Wolffian ducts
 development of the male genital tract, 5–6
 embryonic development, 4, 5
- Wolffian tumor
 ovary, 151–52
- Wt1* gene, 4
- xanthogranulomatous orchio-epididymitis, 34–35
- xanthogranulomatous pyelonephritis, 179
- Y chromosome, 5
- yolk sac tumor
 ovary, 184
 yolk sac tumor (postpubertal type)
 ovary and testis, 94–95
 yolk sac tumor (prepubertal type)
 testis, 99–100
- Zinner syndrome, 130
- Zoon vulvitis, 337
- Zoon’s balanitis, 344